The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Insulin/Insulin-like Growth Factor I Hybrid Receptors Have Different Biological Characteristics Depending on the Insulin Receptor Isoform Involved
Open accessAbstract
The insulin receptor (IR) and the insulin-like growth factor I receptor (IGF-IR) have a highly homologous structure, but different biological effects. Insulin and IGF-I half-receptors can heterodimerize, leading to the formation of insulin/IGF-I hybrid receptors (Hybrid-Rs) that bind IGF-I with high affinity. As the IR exists in two isoforms (IR-A and IR-B), we evaluated whether the assembly of the IGF-IR with either IR-A or IR-B moieties may differently affect Hybrid-R signaling and biological role. Three different models were studied: (a) 3T3-like mouse fibroblasts with a disrupted IGF-IR gene (R(-) cells) cotransfected with the human IGF-IR and with either the IR-A or IR-B cDNA; (b) a panel of human cell lines variably expressing the two IR isoforms; and (c) HepG2 human hepatoblastoma cells predominantly expressing either IR-A or IR-B, depending on their differentiation state. We found that Hybrid-Rs containing IR-A (Hybrid-Rs(A)) bound to and were activated by IGF-I, IGF-II, and insulin. By binding to Hybrid-Rs(A), insulin activated the IGF-I half-receptor beta-subunit and the IGF-IR-specific substrate CrkII. In contrast, Hybrid-Rs(B) bound to and were activated with high affinity by IGF-I, with low affinity by IGF-II, and insignificantly by insulin. As a consequence, cell proliferation and migration in response to both insulin and IGFs were more effectively stimulated in Hybrid-R(A)-containing cells than in Hybrid-R(B)-containing cells. The relative abundance of IR isoforms therefore affects IGF system activation through Hybrid-Rs, with important consequences for tissue-specific responses to both insulin and IGFs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ullrich, A., Gray, A., Tam, A. W., Yang-Feng, T., Tsubokawa, M., Collins, C., Henzel, W., Le Bon, T., Kathuria, S., & Chen, E. (1986) · The EMBO Journal · doi:10.1002/j.1460-2075.1986.tb04528.x · Cited by 1,844
DeChiara, T. M., Efstratiadis, A., & Robertsen, E. J. (1990) · Nature · doi:10.1038/345078a0 · Cited by 1,642
Regulation of Cell Motility by Mitogen-activated Protein Kinase
Klemke, R. L., Cai, S., Giannini, A. L., Gallagher, P. J., Lanerolle, P. D., & Cheresh, D. A. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.2.481 · Cited by 1,235
Frasca, F., Pandini, G., Scalia, P., Sciacca, L., Mineo, R., Costantino, A., Goldfine, I. D., Belfiore, A., & Vigneri, R. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3278 · Cited by 902
Self-citationInsulin Action and the Insulin Signaling Network*
CHEATHAM, B., & KAHN, C. R. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-2-117 · Cited by 881
The IRS-signalling system: A network of docking proteins that mediate insulin action
White, M. F. (1998) · Insulin Action · doi:10.1007/978-1-4615-5647-3_1 · Cited by 667
Distinct and Overlapping Functions of Insulin and IGF-I Receptors
Nakae, J., Kido, Y., & Accili, D. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.6.0452 · Cited by 554
The insulin-like growth factor I receptor: a key to tumor growth?
Baserga, R. (1995) · PubMed · Cited by 552
The IRS-signalling system: A network of docking proteins that mediate insulin action
White, M. F. (1998) · Molecular and Cellular Biochemistry · doi:10.1023/a:1006806722619 · Cited by 534
Monoclonal antibodies to receptors for insulin and somatomedin-C.
Kull, F. C., Jacobs, S., Su, Y. F., Svoboda, M. E., Van Wyk, J. J., & Cuatrecasas, P. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)32449-9 · Cited by 423
Cited by
Insulin-like growth factors and neoplasia
Pollak, M. N., Schernhammer, E. S., & Hankinson, S. E. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1387 · Cited by 1,463
The insulin-like growth factor system and cancer
LeRoith, D., & Roberts, C. T. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00159-9 · Cited by 1,124
Mechanisms of receptor tyrosine kinase activation in cancer
Du, Z., & Lovly, C. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0782-4 · Cited by 1,066
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
Belfiore, A., Frasca, F., Pandini, G., Sciacca, L., & Vigneri, R. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0047 · Cited by 1,033
Self-citationThe many faces of insulin-like peptide signalling in the brain
Fernandez, A. M., & Torres-Alemán, I. (2012) · Nature reviews. Neuroscience · doi:10.1038/nrn3209 · Cited by 872
Insulin and neurodegenerative disease: shared and specific mechanisms
Craft, S., & Stennis Watson, G. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00681-7 · Cited by 830
Reger, M. A., Watson, G. S., Frey, W. H., Baker, L. D., Cholerton, B., Keeling, M. L., Belongia, D. A., Fishel, M. A., Plymate, S. R., Schellenberg, G. D., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.03.016 · Cited by 621
Structural biology of insulin and IGF1 receptors: implications for drug design
De Meyts, P., & Whittaker, J. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd917 · Cited by 582
A Conceptual History of Modern Embryology
(1991) · Springer eBooks · doi:10.1007/978-1-4615-6823-0 · Cited by 557
Prata, C., Zambonin, L., Rizzo, B., Maraldi, T., Angeloni, C., Vieceli Dalla Sega, F., Fiorentini, D., & Hrelia, S. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/3724545 · Cited by 540
The Insulin-Like Growth Factor System and Its Pleiotropic Functions in Brain
Russo, V. C., Gluckman, P. D., Feldman, E. L., & Werther, G. A. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0024 · Cited by 492
Regulated Membrane Trafficking of the Insulin-Responsive Glucose Transporter 4 in Adipocytes
Watson, R. T., Kanzaki, M., & Pessin, J. E. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0011 · Cited by 448
Regulation of muscle mass by growth hormone and IGF‐I
Velloso, C. P. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.153 · Cited by 442
Molecular interactions of the IGF system
Denley, A., Cosgrove, L. J., Booker, G. W., Wallace, J. C., & Forbes, B. E. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.04.004 · Cited by 437
The role of insulin receptors and IGF-I receptors in cancer and other diseases
Frasca, F., Pandini, G., Sciacca, L., Pezzino, V., Squatrito, S., Belfiore, A., & Vigneri, R. (2008) · Archives of Physiology and Biochemistry · doi:10.1080/13813450801969715 · Cited by 410
Self-citationThe role of the insulin-like growth factor-1 system in breast cancer
Christopoulos, P. F., Msaouel, P., & Koutsilieris, M. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0291-7 · Cited by 376
Insulin Receptor Isoforms in Physiology and Disease: An Updated View
Belfiore, A., Malaguarnera, R., Vella, V., Lawrence, M. C., Sciacca, L., Frasca, F., Morrione, A., & Vigneri, R. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00073 · Cited by 375
Self-citationHyper-insulinaemia and cancer, meta-analyses of epidemiological studies
Pisani, P. (2008) · Archives of Physiology and Biochemistry · doi:10.1080/13813450801954451 · Cited by 329
Disrupting insulin-like growth factor signaling as a potential cancer therapy
Sachdev, D., & Yee, D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0080 · Cited by 320
Disrupting Insulin-Like Growth Factor Signaling as a Potential Cancer Therapy
Sachdev, D., & Yee, D. (2008) · AACR Education book · doi:10.1158/aacr.edb-mct-06-0080 · Cited by 314
Hyperinsulinemia in Obesity, Inflammation, and Cancer
Zhang, A. M. Y., Wellberg, E. A., Kopp, J. L., & Johnson, J. D. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0250 · Cited by 305
Livingstone, C. (2013) · Endocrine-Related Cancer · doi:10.1530/erc-13-0231 · Cited by 296
Belfiore, A., & Malaguarnera, R. (2011) · Endocrine-Related Cancer · doi:10.1530/erc-11-0074 · Cited by 272
Self-citationRajpathak, S. N., Gunter, M. J., Wylie‐Rosett, J., Ho, G. Y. F., Kaplan, R. C., Muzumdar, R., Rohan, T. E., & Strickler, H. D. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.919 · Cited by 265
An insulin-like peptide regulates egg maturation and metabolism in the mosquito Aedes aegypti
Brown, M. R., Clark, K. D., Gulia, M., Zhao, Z., Garczynski, S. F., Crim, J. W., Suderman, R. J., & Strand, M. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800478105 · Cited by 263
The brain as an insulin-sensitive metabolic organ
Milstein, J. L., & Ferris, H. A. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101234 · Cited by 259
Ulanet, D. B., Ludwig, D. L., Kahn, C. R., & Hanahan, D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914076107 · Cited by 235
Insulin Regulates Glucagon-Like Peptide-1 Secretion from the Enteroendocrine L Cell
Lim, G. E., Huang, G. J., Flora, N., LeRoith, D., Rhodes, C. J., & Brubaker, P. L. (2009) · Endocrinology · doi:10.1210/en.2008-0726 · Cited by 200
Zhang, H., Pelzer, A. M., Kiang, D. T., & Yee, D. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1712 · Cited by 162
Denley, A., Carroll, J. M., Brierley, G. V., Cosgrove, L., Wallace, J., Forbes, B., & Roberts, C. T. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01447-06 · Cited by 103
“The biological effects of the trans-activated IR subunit versus an activated IR holoreceptor are potentially distinct ( 30 ).”
BackgroundHorváth, V. J., Vittal, H., & Ördög, T. (2005) · Diabetes · doi:10.2337/diabetes.54.5.1528 · Cited by 98
State of the science on brain insulin resistance and cognitive decline due to Alzheimer's disease
Rhea, E. M., Leclerc, M., Yassine, H. N., Capuano, A. W., Tong, H., Petyuk, V. A., Macauley, S. L., Fioramonti, X., Carmichael, O., Calon, F., et al. (2023) · Aging and disease · doi:10.14336/ad.2023.0814 · Cited by 70
“One specific mechanism is through the ability of (αβ)INSR to heterodimerize into hybrids with (αβ)IGF1-R, resulting in a difference in signaling [51, 56, 84-86].”
BackgroundVascular dysfunction as a potential culprit of sarcopenia
Jeon, Y. K., Shin, M. J., Saini, S. K., Custodero, C., Aggarwal, M., Anton, S. D., Leeuwenburgh, C., & Mankowski, R. T. (2021) · Experimental Gerontology · doi:10.1016/j.exger.2020.111220 · Cited by 60
Giuffrida, M. L., Tomasello, M. F., Pandini, G., Caraci, F., Battaglia, G., Busceti, C., Di Pietro, P., Pappalardo, G., Attanasio, F., Chiechio, S., et al. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00297 · Cited by 52
Self-citationInsulin-Like Growth Factor Signaling as a Therapeutic Target in Pancreatic Cancer
Rieder, S., W. Michalski, C., Friess, H., & Kleeff, >. (2011) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152011795677454 · Cited by 50
Turvey, S., Muench, S. P., Issad, T., Fishwick, C. W. G., Kearney, M. T., & Simmons, K. J. (2024) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2024.101607 · Cited by 3
Metadata
- Authors
- Pandini, G., Frasca, F., Mineo, R., Sciacca, L., Vigneri, R., & Belfiore, A.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2002-10
- Volume
- 277
- Issue
- 42
- Pages
- 39684-39695
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1967899512
- Cited by
- 500
- References
- 46
- FWCI
- 10.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.